Erectile dysfunction and cardiovascular risk: a review of current findings

Corona, Giovanni; Rastrelli, Giulia; Isidori, Andrea M.; Pivonello, Rosario; Bettocchi, Carlo; Reisman, Yacov; Sforza, Alessandra; Maggi, Mario

doi:10.1080/14779072.2020.1745632

Cited by 45 publications

(48 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering the side effects of the drugs and their interactions with other drugs, the patient may be harmed. Moreover, clinical examination is necessary because ED can be the first symptom of cardiovascular diseases, also multiple risk factors and comorbidities are generally associated with ED (16). Both to prevent the use of counterfeit medicines and ensure the correct use of FDA-approved PDE5i, patients' awareness should be raised to see a doctor when they have ED.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Erectile dysfunction treatment with Phosphodiesterase-5 Inhibitors: Google trends analysis of last 10 years and COVID-19 pandemic

Değer

Madendere

2021

Arch Ital Urol Androl

View full text Add to dashboard Cite

Objectives: We aimed to analyze the trend change of the most popular Phosphodiesterase-5 Inhibitors (PDE5i) over time and geography by using Google Trends (GT) data in 10 years period and COVID-19 pandemic. Materials and methods: GT is able to generate a “line-graph”, showing how interest has increased or decreased over a period within specific territories. The search values for specific terms are indexed as relative search volume (RSV), which is presented on a scale from 0-100. Avarage annual percentage change (AAPC) and RSV were analyzed to evaluate gain or loss of interest in trends. Search terms were generated for Food and Drug Administration (FDA)-approved PDE5i; tadalafil, sildenafil, vardenafil, avanafil, and their most-used brand names. The data was within “worldwide” from 1 January 2010, to 31 December 2020, using the ‘‘global’’ query category. Results: The overall interest in PDE5i has doubled. Sildenafil has become the most trend PDE5i of today with a regular increase (AAPC: 0.016, p < 0.01). Although the search trend of tadalafil remained almost constant until 2014, the rate of increase in the last 6 years raised and tadalafil has become the 2nd most popular PDE5i recently (AAPC: 0.007, p < 0.01). For vardenafil there has been a decreased interest (AAPC: -0.009, p < 0.01). There is no significant change in avanafil trend (AAPC: 0.000, p: 0.5). All PDE5i interest on GT decreased notably from February to June 2020. But after June, search trends reached the level before the COVID-19 period in a month. Conclusions: These findings show us, with its increasing prevalence, erectile dysfunction (ED) has become a major public health problem. People from different geographies search the internet for ED treatment options. Patients should be informed that ED may be the first sign of many comorbid diseases, and patients with ED should be referred to a health institution for diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Moreover, international trends for each PDE5i individually were searched and shown in a separate figure. All trend and statistical analyses were performed using Microsoft Excel v. 16.0 (Redmond, Wash) and SPSS v.24.0 (SPSS Inc., Chicago, IL, USA).…”

Section: Introductionmentioning

confidence: 99%

Erectile dysfunction treatment with Phosphodiesterase-5 Inhibitors: Google trends analysis of last 10 years and COVID-19 pandemic

Değer

Madendere

2021

Arch Ital Urol Androl

View full text Add to dashboard Cite

show abstract

“…A large body of evidence has clearly documented that subjects with erectile dysfunction (ED) represent a population enriched with metabolic abnormalities [13] and at a high risk of developing CV events [14][15][16]. However, even in this population the specific role played by MetS on metabolic and CV risk stratification is conflicting [17].…”

Section: Introductionmentioning

confidence: 99%

Metabolic Syndrome and Reproduction

Lotti

Marchiani

Corona

et al. 2021

IJMS

View full text Add to dashboard Cite

Metabolic syndrome (MetS) and infertility are two afflictions with a high prevalence in the general population. MetS is a global health problem increasing worldwide, while infertility affects up to 12% of men. Despite the high prevalence of these conditions, the possible impact of MetS on male fertility has been investigated by a few authors only in the last decade. In addition, underlying mechanism(s) connecting the two conditions have been investigated in few preclinical studies. The aim of this review is to summarize and critically discuss available clinical and preclinical studies on the role of MetS (and its treatment) in male fertility. An extensive Medline search was performed identifying studies in the English language. While several studies support an association between MetS and hypogonadism, contrasting results have been reported on the relationship between MetS and semen parameters/male infertility, and the available studies considered heterogeneous MetS definitions and populations. So far, only two meta-analyses in clinical and preclinical studies, respectively, evaluated this topic, reporting a negative association between MetS and sperm parameters, testosterone and FSH levels, advocating, however, larger prospective investigations. In conclusion, a possible negative impact of MetS on male reproductive potential was reported; however, larger studies are needed.

show abstract

“…Ця дисфункція є предиктором майбутніх коронарних подій і може бути діагностованою визначенням рівнів циркулюючих у крові маркерів. Тому наявність ЕД може спонукати до обстеження стану серцево-судинної системи в чоловіків без симптомів ССЗ [33]. Ендотелін-1 (ЕT-1) належить до найпотужніших пептидів, похідних ендотелію, із судиноскорочувальною дією, рівні якого змінюються у хворих на ЦД із хронічними ускладненнями, атеросклерозом і серцево-судинними захворюваннями.…”

Section: ключові слова: цукровий діабет; чоловік; еректильна дисфункція тестостеронunclassified

Erectile dysfunction in men with diabetes (literature review) Part 1

Luchytskyy

Luchytskiy

2022

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

The first part of the review article highlights modern views on the prevalence, etiology and features of the pathogenesis of erectile dysfunction (ED) in men with diabetes mellitus. Google Scholar and PubMed databases were used to search for literature sources. The role of comorbid diseases in the development of ED in men with diabetes mellitus has been shown. The generalized data on the main clinical manifestations of erectile dysfunction, methods of its diagnosis and treatment are given. A number of epidemiological studies over the past 20 years have found that erectile dysfunction in men with diabetes may be an early marker of cardiovascular complications. Thus, in the algorithm for ED diagnosis in patients with diabetes it is necessary to conduct a thorough examination of the cardiovascular system. Numerous literature sources indicate an important role in the correction of androgen deficiency in men with type 2 diabetes, in order to enhance the effectiveness of phosphodiesterase type 5 inhibitors. Erectile dysfunction involves a change in any of the components of an erectile response. ED can negatively affect a man’s quality of life because most patients experience symptoms of depression and anxiety related to their sexual capabilities. These symptoms also affect a partner’s sexual experience and the couple’s quality of life. Clinical features of ED have many key features in the anamnesis, including some physical signs during examination depending on a type of diabetes. With age, comorbid conditions play an increasing role in the development of ED. Diabetes mellitus, cardiovascular diseases, obesity can lead to the development of ED before accelerated deterioration of erectile function and disorders at the molecular level of the mechanisms underlying erection. Patients with diabetes and ED have higher scores on the depression rating scale, and poorer overall health and quality of life. Early detection of ED in individuals with diabetes can improve the overall health and quality of life of patients. Patients with diabetes with poor glycemic control and older age are more likely to develop severe ED, which further exacerbates an already compromised health and quality of life. According to the National Health and Nutrition Examination Survey (2001–2002), diabetes mellitus is a modified risk factor independently associated with the development of ED (odds ratio (OR) 2.69), obesity (OR 1.60), smoking (OR 1.74) and hypertension (OR 1.56). Erectile dysfunction is a common complication of diabetes, and diabetes is a risk factor for ED; men with diabetes are three times more likely to have ED.

show abstract

Erectile dysfunction and cardiovascular risk: a review of current findings

Cited by 45 publications

References 83 publications

Erectile dysfunction treatment with Phosphodiesterase-5 Inhibitors: Google trends analysis of last 10 years and COVID-19 pandemic

Erectile dysfunction treatment with Phosphodiesterase-5 Inhibitors: Google trends analysis of last 10 years and COVID-19 pandemic

Metabolic Syndrome and Reproduction

Erectile dysfunction in men with diabetes (literature review) Part 1

Contact Info

Product

Resources

About